Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Researchers investigate the risk of incident thyroid cancer among patients treated with glucagon-like peptide-1 receptor ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

The good news is that the risk for thyroid cancer linked to GLP-1 drugs appears low, but higher detections in the first year, ...

Ozempic and other weight loss drugs have found their home in Kentucky, even though researchers from Washington University in ...

The research found that participants who used the class of drugs which includes Wegovy and Ozempic had a lower risk of 42 ...

The study in Nature Medicine reveals that alongside weight loss benefits, GLP-1 medications like Ozempic and Mounjaro may ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Whether it is prescribed for diabetes or weight loss, Ozempic and other weight- loss drugs have found their home in Kentucky, ...